ArticleInternational journal of molecular medicine2018

ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells.

Yang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.